ES2188985T3 - Seleccion enantiomerica y evolucion enantiomerica de acidos nucleicos. - Google Patents
Seleccion enantiomerica y evolucion enantiomerica de acidos nucleicos.Info
- Publication number
- ES2188985T3 ES2188985T3 ES97942899T ES97942899T ES2188985T3 ES 2188985 T3 ES2188985 T3 ES 2188985T3 ES 97942899 T ES97942899 T ES 97942899T ES 97942899 T ES97942899 T ES 97942899T ES 2188985 T3 ES2188985 T3 ES 2188985T3
- Authority
- ES
- Spain
- Prior art keywords
- enantiomeric
- nucleic acids
- evolution
- selection
- molecula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000007523 nucleic acids Chemical class 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 title 1
- 239000002253 acid Substances 0.000 abstract 2
- 150000007513 acids Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1048—SELEX
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Bioinformatics & Computational Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Ecology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Tea And Coffee (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
SE EXPONE UN PROCEDIMIENTO PARA IDENTIFICAR Y PRODUCIR ACIDOS L-NUCLEICOS, QUE INTERACCIONAN CON UNA MOLECULA-BLANCO QUE TIENE UNA CONFIGURACION NATURAL, ASI COMO LOS ACIDOS LNUCLEICOS OBTENIDOS POR ESTE PROCEDIMIENTO. SE EXPONEN IGUALMENTE EL USO DE ACIDOS D-NUCLEICOS QUE SE FIJAN A LA ANTIPODA OPTICA DE LA MOLECULA-BLANCO COMO MATRIZ PARA PRODUCIR ACIDOS L-NUCLEICOS CON SECUENCIA IDENTICA, Y MEDICAMENTOS Y CONJUNTOS QUE CONTIENEN EL ACIDO L-NUCLEICO EXPUESTO.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP96113953 | 1996-08-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2188985T3 true ES2188985T3 (es) | 2003-07-01 |
Family
ID=8223148
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES97942899T Expired - Lifetime ES2188985T3 (es) | 1996-08-30 | 1997-08-29 | Seleccion enantiomerica y evolucion enantiomerica de acidos nucleicos. |
Country Status (8)
Country | Link |
---|---|
US (1) | US6605713B1 (es) |
EP (1) | EP0934331B1 (es) |
JP (1) | JP2001504448A (es) |
AT (1) | ATE228529T1 (es) |
AU (1) | AU743469C (es) |
DE (1) | DE59708838D1 (es) |
ES (1) | ES2188985T3 (es) |
WO (1) | WO1998008856A2 (es) |
Families Citing this family (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2799465B1 (fr) * | 1999-10-12 | 2004-02-13 | Centre Nat Rech Scient | Peptides ayant une activite de stimulation de la reponse immunitaire et de regeneration tissulaire |
US20050208487A1 (en) * | 2000-05-26 | 2005-09-22 | Jens Burmeister | Immobilized nuckeic acids and uses thereof |
DE10122862A1 (de) * | 2001-05-11 | 2002-11-21 | Noxxon Pharma Ag | GnRH bindende Nukleinsäure |
DE10122847A1 (de) * | 2001-05-11 | 2002-11-21 | Noxxon Pharma Ag | Enterotoxin B bindende Nukleinsäure |
DK1264603T3 (da) * | 2001-06-10 | 2010-04-26 | Noxxon Pharma Ag | Anvendelse af L-polynukleotider til in vivo-billeddannelse |
EP1288309A1 (de) * | 2001-08-30 | 2003-03-05 | Noxxon Pharma AG | Verfahren zur Markierung von L-Nukleinsäuren |
EP1306382A1 (de) * | 2001-10-26 | 2003-05-02 | Noxxon Pharma AG | Modifizierte L-Nukleinsäure |
ES2629615T3 (es) * | 2001-10-26 | 2017-08-11 | Noxxon Pharma Ag | Ácido L-nucleico modificado |
US20030219422A1 (en) * | 2001-11-15 | 2003-11-27 | Noxxon Pharma Ag | Allosteric ribozymes and uses thereof |
DE10209821A1 (de) | 2002-03-06 | 2003-09-25 | Biotechnologie Ges Mittelhesse | Kopplung von Proteinen an ein modifiziertes Polysaccharid |
DE10211558A1 (de) * | 2002-03-15 | 2003-10-09 | Noxxon Pharma Ag | Neue Formen RNAi |
WO2003093504A1 (de) * | 2002-05-06 | 2003-11-13 | Noxxon Pharma Ag | Verfahren zur amplifikation von nukleinsäuren |
CN1655827B (zh) | 2002-05-27 | 2010-06-23 | 佩尔·松内·霍尔姆 | 腺病毒和编码其的核酸的新应用 |
EP1386972A1 (en) * | 2002-08-01 | 2004-02-04 | Noxxon Pharma AG | Method and apparatus for designing a nucleic acid having a desired property |
MXPA05001766A (es) | 2002-08-14 | 2005-08-19 | Atugen Ag | Uso de proteina quinasa n beta. |
EP1393742A1 (en) | 2002-08-14 | 2004-03-03 | atugen AG | Use of protein kinase N beta |
WO2004035618A2 (en) | 2002-10-15 | 2004-04-29 | Intercell Ag | Nucleic acids coding for adhesion factor of group b streptococcus, adhesion factors of group b streptococcus and further uses thereof |
ATE420102T1 (de) | 2002-10-18 | 2009-01-15 | Silence Therapeutics Ag | An der metastase beteiligter faktor und verwendungen dafür |
EP2287311A1 (en) | 2003-03-04 | 2011-02-23 | Intercell AG | Streptococcus pyogenes antigens |
CA2520868A1 (en) | 2003-03-31 | 2004-10-14 | Intercell Ag | Staphylococcus epidermidis antigens |
EP2311991A1 (en) | 2003-04-15 | 2011-04-20 | Intercell AG | S. pneumoniae antigens |
EP2289907A3 (en) | 2003-05-07 | 2011-08-31 | Intercell AG | Streptococcus agalactiae antigens I + II |
EP2327720A1 (en) | 2003-05-30 | 2011-06-01 | Intercell AG | Enterococcus antigens |
WO2005014655A2 (en) | 2003-08-08 | 2005-02-17 | Fresenius Kabi Deutschland Gmbh | Conjugates of hydroxyalkyl starch and a protein |
CA2546178A1 (en) | 2003-11-14 | 2005-06-09 | Per Sonne Holm | New use of adenovirus and nucleic acids coding therefor |
US9492400B2 (en) | 2004-11-04 | 2016-11-15 | Massachusetts Institute Of Technology | Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals |
EP2992902A1 (en) | 2004-12-27 | 2016-03-09 | Silence Therapeutics GmbH | Lipid complexes coated with peg and their uses |
US20060199207A1 (en) * | 2005-02-24 | 2006-09-07 | Matysiak Stefan M | Self-assembly of molecules using combinatorial hybridization |
SG161311A1 (en) * | 2005-05-04 | 2010-05-27 | Noxxon Pharma Ag | Novel use of spiegelmers |
WO2007070682A2 (en) | 2005-12-15 | 2007-06-21 | Massachusetts Institute Of Technology | System for screening particles |
MX2008008548A (es) | 2005-12-30 | 2008-09-10 | Evonik Roehm Gmbh | Peptidos utiles como petidos penetradores de celulas. |
JP4984990B2 (ja) * | 2006-03-28 | 2012-07-25 | 富士通株式会社 | 機能性分子の製造方法 |
EP2992875A1 (en) | 2006-04-20 | 2016-03-09 | Silence Therapeutics GmbH | Lipoplex formulations for specific delivery to vascular endothelium |
US8367113B2 (en) | 2006-05-15 | 2013-02-05 | Massachusetts Institute Of Technology | Polymers for functional particles |
WO2007150030A2 (en) | 2006-06-23 | 2007-12-27 | Massachusetts Institute Of Technology | Microfluidic synthesis of organic nanoparticles |
CN102321626B (zh) | 2006-07-21 | 2014-12-10 | 赛伦斯治疗有限公司 | 用于抑制蛋白激酶3表达的方法 |
EP2289906A1 (en) | 2006-09-15 | 2011-03-02 | Intercell AG | Borrelia antigens |
EP1913955A1 (en) | 2006-10-19 | 2008-04-23 | Gerhard, Markus | Novel method for treating H.pylori infections |
WO2008119571A2 (en) * | 2007-01-03 | 2008-10-09 | Novo Nordisk A/S | Nucleic acid myostatin antagonist aptamers obtained by (mirror- image) selex |
US9217129B2 (en) | 2007-02-09 | 2015-12-22 | Massachusetts Institute Of Technology | Oscillating cell culture bioreactor |
WO2008124632A1 (en) | 2007-04-04 | 2008-10-16 | Massachusetts Institute Of Technology | Amphiphilic compound assisted nanoparticles for targeted delivery |
AU2008248755A1 (en) | 2007-05-02 | 2008-11-13 | Intercell Ag | Klebsiella antigens |
US20100203075A1 (en) | 2007-06-18 | 2010-08-12 | Intercell Ag | Chlamydia antigens |
US8183221B2 (en) | 2007-09-05 | 2012-05-22 | Medtronic, Inc. | Suppression of SCN9A gene expression and/or function for the treatment of pain |
EP2045326A1 (en) * | 2007-10-05 | 2009-04-08 | Bayer CropScience AG | Method for identifying the interaction partner of an active agent |
MX350501B (es) | 2007-10-12 | 2017-09-07 | Massachusetts Inst Technology | Nanotecnologia de vacuna. |
WO2009053691A1 (en) † | 2007-10-22 | 2009-04-30 | Pronota Nv | Method of selecting aptamers |
US8591905B2 (en) | 2008-10-12 | 2013-11-26 | The Brigham And Women's Hospital, Inc. | Nicotine immunonanotherapeutics |
US8277812B2 (en) | 2008-10-12 | 2012-10-02 | Massachusetts Institute Of Technology | Immunonanotherapeutics that provide IgG humoral response without T-cell antigen |
US8343497B2 (en) | 2008-10-12 | 2013-01-01 | The Brigham And Women's Hospital, Inc. | Targeting of antigen presenting cells with immunonanotherapeutics |
US8343498B2 (en) | 2008-10-12 | 2013-01-01 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunonanotherapeutics |
EP2393504B1 (de) * | 2009-02-06 | 2013-06-05 | Freie Universität Berlin | Ein l-ribozym enthaltende pharmazeutische zusammensetzung zur behandlung von nebenwirkungen durch gabe von spiegelmeren |
EP2405938A2 (en) | 2009-02-13 | 2012-01-18 | Intercell AG | Nontypable haemophilus influenzae antigens |
DE102009058769A1 (de) | 2009-12-16 | 2011-06-22 | MagForce Nanotechnologies AG, 10589 | Temperaturabhängige Aktivierung von katalytischen Nukleinsäuren zur kontrollierten Wirkstofffreisetzung |
WO2011098262A2 (en) | 2010-02-09 | 2011-08-18 | Universität Bremen | P19arf, hmga2 and mdm2 for use in the diagnosis and treatment of aberrant cell growth |
KR20130108983A (ko) | 2010-05-26 | 2013-10-07 | 셀렉타 바이오사이언시즈, 인크. | 커플링되지 않은 애주번트를 갖는 나노담체 조성물 |
WO2012022496A2 (en) | 2010-08-19 | 2012-02-23 | Per Sonne Holm | Method for killing tumor stem cells |
US20140056811A1 (en) | 2010-12-27 | 2014-02-27 | Compugen Ltd. | New cell-penetrating peptides and uses thereof |
DE102010056610A1 (de) * | 2010-12-31 | 2012-07-05 | Volker A. Erdmann | Pharmazeutische Zusammensetzung enthaltend L-DNA |
KR102080142B1 (ko) | 2011-01-10 | 2020-02-21 | 아프타리온 바이오테크 아게 | 목표 분자에 결합력을 갖는 l-형 핵산 및 이를 제조하는 방법 |
EP2734531A1 (en) | 2011-07-22 | 2014-05-28 | Université de Strasbourg | Phospholipid-detergent conjugates and uses thereof |
EP2753697A1 (en) | 2011-09-05 | 2014-07-16 | ETH Zürich | Biosynthetic gene cluster for the production of peptide/protein analogues |
WO2013050540A1 (en) | 2011-10-05 | 2013-04-11 | University Of Bremen | Wnt4 and med12 for use in the diagnosis and treatment of tumor diseases |
EP2785839A2 (en) | 2011-11-30 | 2014-10-08 | University of Bremen | Expression of mirnas in placental tissue |
JP2015521041A (ja) | 2012-05-16 | 2015-07-27 | サイレンス・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Pkn3阻害剤投与のためのバイオマーカーとしてのvegfr1の使用 |
ES2965777T3 (es) | 2012-05-16 | 2024-04-16 | Aptarion Biotech Ag | Síntesis enzimática de ácidos L-nucleicos |
CN112587671A (zh) | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
CA2883264A1 (en) | 2012-10-15 | 2014-04-24 | Universitat Zurich Prorektorat Mnw | Bispecific her2 ligands for cancer therapy |
EP2759602A1 (en) | 2013-01-25 | 2014-07-30 | Charité - Universitätsmedizin Berlin | Non-invasive prenatal genetic diagnostic methods |
EP2837939A1 (en) | 2013-08-13 | 2015-02-18 | Technische Universität München | Method for the detection of H.pylori infection |
EP3065744B1 (en) | 2013-11-04 | 2021-04-21 | Noxxon Pharma AG | A ccl2 antagonist for use in treating proteinuria |
KR20160079126A (ko) * | 2013-11-20 | 2016-07-05 | 녹손 파르마 아게 | 효소를 통한 l-핵산의 합성 |
KR20160095003A (ko) | 2013-12-05 | 2016-08-10 | 사일런스 테라퓨틱스 게엠베하 | 폐 특이적 전달을 위한 수단 |
CN114716555A (zh) | 2014-01-10 | 2022-07-08 | 博笛生物科技有限公司 | 靶向表达egfr的肿瘤的化合物和组合物 |
CA2937447A1 (en) | 2014-01-29 | 2015-08-06 | Vaxine Pty Ltd | New target for diabetes treatment and prevention. |
ES2796090T3 (es) | 2014-02-10 | 2020-11-25 | Inst Curie | Uso de moduladores MCOLN-1 para regular la migración celular |
AU2015286043B2 (en) | 2014-07-09 | 2020-08-20 | Birdie Biopharmaceuticals Inc. | Anti-PD-L1 combinations for treating tumors |
CN105233291A (zh) | 2014-07-09 | 2016-01-13 | 博笛生物科技有限公司 | 用于治疗癌症的联合治疗组合物和联合治疗方法 |
CN112587672A (zh) | 2014-09-01 | 2021-04-02 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-pd-l1结合物 |
EP3000483A1 (en) | 2014-09-29 | 2016-03-30 | Charité - Universitätsmedizin Berlin | Means and methods for the diagnosis and treatment of neurodegenerative diseases |
WO2016196218A1 (en) | 2015-05-31 | 2016-12-08 | Curegenix Corporation | Combination compositions for immunotherapy |
EP3264092A1 (en) | 2016-07-01 | 2018-01-03 | Centogene AG | Use of lyso-gb1 as druggable target |
EP3315125A1 (en) | 2016-10-31 | 2018-05-02 | Silence Therapeutics (London) Ltd | Lipid nanoparticle formulation |
EP3555138A1 (en) | 2016-12-16 | 2019-10-23 | Université de Bordeaux | Mmp9 inhibitors and uses thereof in the prevention or treatment of a depigmenting disorder |
EP3421485A1 (en) | 2017-06-30 | 2019-01-02 | Université de Strasbourg | Peptides for treatment and prevention of hyperglycaemia |
EP3521828A1 (en) | 2018-01-31 | 2019-08-07 | Centogene AG | Method for the diagnosis of hereditary angioedema |
CA3092907A1 (en) | 2018-03-05 | 2019-09-12 | Klinikum Rechts Der Isar Der Technischen Universitat Munchen | Treatment of tumors by a combination of an oncolytic adenovirus and a cdk4/6 inhibitor |
CA3149497A1 (en) | 2019-08-09 | 2021-02-18 | Nutcracker Therapeutics, Inc. | Methods and apparatuses for manufacturing for removing material from a therapeutic composition |
AU2020342594A1 (en) | 2019-09-05 | 2022-03-10 | Klinikum Rechts Der Isar Der Technischen Universität München | Treatment of tumors by a combination of an oncolytic adenovirus, a CDK4/6 inhibitor and a further therapeutically active agent |
AU2020407285A1 (en) | 2019-12-20 | 2022-08-11 | CureVac SE | Lipid nanoparticles for delivery of nucleic acids |
AU2022336209A1 (en) | 2021-09-03 | 2024-01-18 | CureVac SE | Novel lipid nanoparticles for delivery of nucleic acids |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11505527A (ja) | 1995-05-03 | 1999-05-21 | ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ | 鏡像異性体リガンドの同定 |
US5780221A (en) * | 1995-05-03 | 1998-07-14 | Whitehead Institute For Biomedical Research | Identification of enantiomeric ligands |
GB9609722D0 (en) | 1996-05-09 | 1996-07-10 | Smithkline Beecham Corp | Novel method |
-
1997
- 1997-08-29 WO PCT/EP1997/004726 patent/WO1998008856A2/de active Search and Examination
- 1997-08-29 ES ES97942899T patent/ES2188985T3/es not_active Expired - Lifetime
- 1997-08-29 JP JP51129798A patent/JP2001504448A/ja active Pending
- 1997-08-29 EP EP97942899A patent/EP0934331B1/de not_active Expired - Lifetime
- 1997-08-29 AT AT97942899T patent/ATE228529T1/de not_active IP Right Cessation
- 1997-08-29 DE DE59708838T patent/DE59708838D1/de not_active Expired - Lifetime
- 1997-08-29 AU AU44568/97A patent/AU743469C/en not_active Expired
- 1997-08-29 US US09/254,126 patent/US6605713B1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
DE59708838D1 (de) | 2003-01-09 |
JP2001504448A (ja) | 2001-04-03 |
EP0934331A2 (de) | 1999-08-11 |
AU743469C (en) | 2004-02-12 |
EP0934331B1 (de) | 2002-11-27 |
WO1998008856A2 (de) | 1998-03-05 |
US6605713B1 (en) | 2003-08-12 |
WO1998008856A3 (de) | 1998-05-07 |
AU4456897A (en) | 1998-03-19 |
AU743469B2 (en) | 2002-01-24 |
ATE228529T1 (de) | 2002-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2188985T3 (es) | Seleccion enantiomerica y evolucion enantiomerica de acidos nucleicos. | |
ES2000015T3 (es) | Superficies polimericas modificadas y metodo de preparacion de las mismas. | |
DE69016097D1 (de) | Entladungslampe mit Verwendung von akustischen Resonanzschwingungen zur Sicherstellung eines hohen Wirkungsgrades. | |
ES2105999T3 (es) | Procedimiento para la preparacion industrial de fosfatidilserina. | |
ATE282176T1 (de) | Beleuchtungsvorrichtung für nicht-emitierende anzeige | |
AR031185A1 (es) | Casquillo de empalme interacoplable, de baja perdida, para fibras opticas y un metodo para la fabricacion de este | |
ES2186690T3 (es) | Acido nucleico enzimatico que contiene no-nucleotidos. | |
ES2068202T3 (es) | Composicion liquida suavizante para prendas de ropa. | |
ES2102984T3 (es) | Medios para el crecimiento de celulas y procedimiento para preparar los mismos. | |
ES2133650T3 (es) | Acristalamiento de aviones con estabilidad a la luz, estabilidad quimica y estabilidad dimensional bajo calor. | |
EA199900580A1 (ru) | Фармацевтические производные аминофосфоновой кислоты | |
ES2102312B1 (es) | Procedimiento para la cristalizacion del iopamidol | |
ES2104766T3 (es) | Agentes tensioactivos derivados de esteres de acido sulfosuccinico. | |
ES2139143T3 (es) | Gel micro-mesoporoso y procedimiento para su preparacion. | |
SE9901306D0 (sv) | Improved TIRF chamber | |
ES493536A0 (es) | Procedimiento para revestir una caja catodica que tiene una pluralidad de catodos foraminados con cavidad, con un dia- fragma sintetico. | |
EA199900842A1 (ru) | Модуляторы функции рецепторов, принадлежащих к семейству рецепторов tnf/ngf | |
AR009819A1 (es) | Inhibidores de la proteasa proteinicos estabilizados y sus variantes | |
ES2057861T3 (es) | Medio de almacenamiento de datos y metodos para registrar y leer datos. | |
EA200000069A1 (ru) | Способ получения 4-замещенных-1h-индол-3-глиоксамидов | |
ES2022865B3 (es) | Compuestos azoicos que contienen grupos ciano, procedimientos para su obtencion y aplicacion de los mismos como colorantes. | |
IT7829874A0 (it) | Cementi rinforzati con fibre di vetro e processo per la loro fabbricazione. | |
ES2038118T3 (es) | Procedimiento para producir una disposicion de promotores, que son activos en estreptomicetos. | |
DK679387A (da) | Indikatorlampe til indstoebning i beton eller lignende | |
BR9709564A (pt) | Processo para produzir compostos alifaticos de mais baixo teor de enxofre e uso de um extrator morfolinico |